California-Bred Warren’s Showtime Smokes Late To Take $75,000 China Doll Stakes By A Half Length; Warren Homebred, Ridden By Velez & Trained By Lewis, Gets Mile On Turf 1:36.24 ARCADIA, Calif. (March 7, 2020)–Mid-pack among a field of 13 sophomore fillies heading to the far turn, Benjamin and Sally Warren’s homebred Warren’s Showtime somehow found room a furlong from home and roared up the rail to take Saturday’s $75,000 China Doll Stakes by a half length. A California-bred daughter of red hot sire Clubhouse Ride, Warren’s Showtime, who was ridden by apprentice Jorge Velez and is trained by Craig Lewis, got a mile on turf in 1:36.24.A winner of the California Cup Oaks at one mile on turf here Jan. 18, Warren’s Showtime was off as the narrow 3-1 favorite over highly regarded Irish-bred Stela Star and paid $8.00, $4.20 and $3.00.Out of Warren’s Grade I winning Affirmative mare Warren’s Veneda, Warren’s Showtime picked up her third stakes win, all in combination with Velez, and registered her fourth overall win from seven starts. With the winner’s share of $45,000, she now has earnings of $281,271.Ridden by Joel Rosario and trained by John Sadler, Stela Star was the second choice at 3-1, as she attracted roughly $900.00 less than the winner, returning $4.80 and $3.60.Head and head for the lead with longshot Roadrunner’s Honor to the far turn, Bella Vita spurted two lengths clear a furlong out, but was no match for the top two late. Ridden by Flavien Prat, California-bred Bella Vita was off at 4-1 and paid $3.80 to show.Fractions on the race were 23.43, 47.84, 1:12.30 and 1:24.37.
3 RECORD IN QUALIFYINGPanama finished third in the CONCACAF fifth round qualification stage, also known as the ‘Hexagonal’. They claimed the final automatic qualification spot on goal difference, with Honduras – equal with Panama on 13 points – forced into an inter-confederation play-off against Australia which they lost.Panama’s final group game, a 2-1 victory over Costa Rica which secured them enough points to reach the World Cup, was mired in controversy. Johan Venegas’ opening goal was cancelled out by Blas Perez, who was credited with a goal that appeared to be both a hand-ball and in fact didn’t cross the goal line at all. But the strike stood, and with just minutes remaining, Roman Torres scored the all-important winning goal.Despite that victory, the USA still could have overtaken Panama to book their place in Russia later that day, but they were defeated in Trinidad and Tobago thus failed to qualify for a World Cup for the first time since 1986.TOURNAMENT PREPARATIONSPanama had one home and one away match prior to the big kick-off. They hosted Northern Ireland in Panama City on May 29, played out a goalless draw, and then visited Oslo to face Norway on June 6, losing 1-0.BASE CAMPOlympic Sports Centre, Saransk.PROBABLE LINE-UP Panama take part in their first World Cup this summer. talkSPORT.com take an in-depth look at the Group G nation…MANAGERHernan Dario Gomez was named as Panama manager in 2014, taking over from ex-Paris Saint-Germain and Cagliari striker Julio Dely Valdes. Gomez has overseen 66 games in charge, guiding Panama to 24 victories (W24, D18, L24). Taking nations to their debut World Cup finals is no new feat for coach Gomez; he successfully led his home nation Colombia to the 1998 finals in France Ecuador to the 2002 edition in Japan and South Korea. As a player he did not represent Colombia, but he enjoyed a relatively prosperous domestic career, appearing for both Medellin (1975-80) and Atletico National (1980-84).CAPTAINRoman Torres was named Panama captain for the first time in 2015, when his nation reached the semi-finals of that year’s Gold Cup. Torres is perhaps Panama’s most reliable defender, playing his domestic football for Seattle Sounders of MLS. The 32-year-old has made 108 appearances for his country since debuting in 2005, and it was his 88th minute winning goal against Costa Rica in Panama’s final qualifying match, played in October 2017, that booked the nation’s place at their first ever World Cup finals.KEY PLAYERPanama’s top scorer throughout qualifying with 11 goals was forward Blas Perez. The 37-year-old has played in a number of countries throughout his 20-year career, including his homeland, as well as Uruguay, Colombia, Spain, Mexico and the United States. He has represented Municipal of Guatemala since 2017, and has totalled an impressive 14 goals in just 13 appearances this season. Perez made his international debut in 2001, and has gone on to win 113 caps for Panama, scoring 43 goals in the process.ONE TO WATCHPanama’s squad is set to be one of the oldest at the entire World Cup, but one of the brightest sparks is 22-year-old Michael Amir Murillo. The right-back plays for New York Red Bulls in MLS, and has so far won 21 caps for his nation. He joined NYRB last February, and now appears to have fully established himself as a starter for the club. His tactical flexibility is impressive, as he can play either as a traditional right-back, or as a right-sided centre-back in a three-man defence, or even in a holding midfield role. PSV of Eindhoven are said to be interested in Murillo, and a strong showing in Russia could tempt other European clubs to make a move for the youngster.FIXTURESMonday, June 18: BELGIUM v Panama (Fisht Stadium, Sochi) – kick-off 16:00Sunday, June 24: ENGLAND v Panama (Nizhny Novgorod Stadium, Nizhny Novgorod) – kick-off 13:00Thursday, June 28: Panama v TUNISIA (Mordovia Arena, Saransk) – kick-off 19:00KITS talkSPORT will be with listeners all day and all night at this year’s 2018 FIFA World Cup™ with over 800 hours of World Cup content and all 64 games live across the talkSPORT network. 3
Reviewed by Alina Shrourou, B.Sc. (Editor)Sep 19 2018An analysis of the NRG Oncology clinical trial NRG-GY003 suggests that adding ipilimumab, a monoclonal antibody that targets the protein receptor CTLA-4, to a regimen with the checkpoint inhibitor nivolumab could improve the proportion with tumor response and progression-free survival hazard rates for women with recurrent epithelial ovarian cancer. These results were presented as a late-breaking abstract oral presentation at the 17th Biennial Meeting of the International Gynecological Cancer Society (IGCS) in Kyoto, Japan. This trial was sponsored by the Division of Cancer Treatment and Diagnosis, National Cancer Institute (NCI) and the agents were provided to NCI by Bristol Myers Squibb under the cooperative research and development agreements between Bristol Myers Squibb and NCI for the development of nivolumab and ipilimumab.NRG-GY003 assessed the difference in tumor response proportions in 100 women between two treatment regimens over a period of six months. Participants on this trial were randomly assigned to either the first treatment arm (TA1) which received nivolumab alone, or the second arm (TA2) which received a combination of ipilimumab and nivolumab followed by maintenance nivolumab. Tumor response proportions were evaluated through RECIST 1.1 and secondary analyses included progression-free survival (PFS), overall survival (OS), and adverse events (AEs).Related StoriesTrends in colonoscopy rates not aligned with increase in early onset colorectal cancerSugary drinks linked to cancer finds studyBacteria in the birth canal linked to lower risk of ovarian cancerWithin six months from randomization, 6 (12.2%) responses occurred in TA1 and 16 (31.4%) responses occurred in TA2 (the odds ratio is 3.28 with 85% confidence that it is greater than 1.90). Following the six-month evaluation period, one additional response appeared on TA2. The platinum-free interval stratified hazard ratio (HR) for progression-free survival was 0.528 (95% CI 0.339 to 0.821) and the respective HR for death was 0.789 (95% CI 0.439-1.418). Adverse events (grade 3 or higher) were more prevalent in TA2, however, there were no new safety signals and no treatment-related deaths.”From my perspective, this is the first evidence that the addition of CTLA4 targeted therapy to PD-1 targeted therapy in patients with ovarian cancer may be more beneficial than PD-1 targeted therapy alone. Future directions could include a trial combining nivolumab and ipilimumab in front line therapy as an adjunct to standard chemotherapy,” stated Robert A. Burger, MD, the abstract Lead Author and Professor of Obstetrics and Gynecology at the Perelman School of Medicine at the University of Pennsylvania.The trial was not powered to detect a difference in overall survival, and there was no preliminary evidence to indicate a detrimental effect from TA2.Source: https://www.nrgoncology.org/